Atopic Dermatitis

James Song, MD, FAAD, discusses how ruxolitinib cream addresses a significant treatment gap in pediatric atopic dermatitis by providing a non-steroidal topical option with efficacy comparable to medium-potency corticosteroids but without the associated safety concerns.

James Song, MD, FAAD, discusses how the treatment of pediatric atopic dermatitis (AD) demands personalized consideration of disease severity, patient age, affected areas, and treatment history. Ruxolitinib cream may address gaps by providing a nonsteroidal alternative with fewer adverse effects, potentially delaying or reducing systemic therapy needs.

Raj Chovatiya, MD, PhD, MSCI, reviews the benefits of Revolutionizing Atopic Dermatitis as a disease-specific conference.

Tapinarof offers sustained relief for atopic dermatitis, enabling treatment-free periods and long-term disease control—even in young children.

The funds will target programs for chronic pruritus, atopic dermatitis, and other inflammatory skin conditions.

Untreated or undertreated AD can lead to poor sleep, infections, and stunted development.

The company also announced in a press release that the product received the Seal of Acceptance by the NEA.

Jennifer Soung, MD, discusses how convenience and ease of use influence treatment adherence and how a new topical JAK inhibitor could enhance real-world outcomes by simplifying application and improving patient compliance.

Jennifer Soung, MD, discusses how ruxolitinib cream, if approved for use in ages 2–11, could become a valuable addition to the treatment landscape for pediatric atopic dermatitis by offering a non-steroidal option for managing inflammation and symptoms.

Jennifer Soung, MD, discusses how having more nonsteroidal options for long-term atopic dermatitis management is crucial, especially for younger children, to minimize potential side effects and support safer, sustained treatment.

Jennifer Soung, MD, discusses how the biggest frustrations parents express about current treatment options for their children with AD, including limited effectiveness, side effects, and the lack of long-term solutions.

Jennifer Soung, MD, discusses how pediatric atopic dermatitis (AD) burdens entire families through sleep disruption and emotional toll. Parents seek effective nonsteroidal options beyond current treatments. Convenient topical Janus kinase (JAK) inhibitors could improve adherence and outcomes.

Bill Damsky, MD, PhD, pioneers molecular diagnostics to close the gap between research and clinical care in inflammatory skin disease.

Raj Chovatiya, MD, PhD, MSCI, discusses his approach to diagnosing and treating chronic hand eczema.

Raj Chovatiya, MD, PhD, MSCI, explores case-based approaches to managing atopic dermatitis, focusing on treatment strategies, challenges, and clinical insights for improving patient outcomes.

Recent literature shows that children from racial minority groups with lower-income families have higher disease prevalence but reduced access to care.

Alphyn Biologics has dosed the first patient in a global phase 2b trial of zabalafin hydrogel for mild to moderate atopic dermatitis.

Current JAK inhibitors are approved only for those 12 and older, leaving younger patients without access.

The study found dupilumab-treated patients had the highest probability of remaining infection-free over 52 weeks.

Aaron Farberg, MD, discuss how to educate parents about the potential adverse effects of a new therapy while also reassuring them about its overall safety profile by providing clear, evidence-based information and emphasizing the rigorous testing and monitoring processes.

Aaron Farberg, MD, discuss how appropriate monitoring, including regular assessments of growth, potential side effects, and laboratory tests to evaluate liver function and hematologic parameters, would be necessary when prescribing a topical JAK inhibitor to a younger child (age 2-11 years).

Aaron Farberg, MD, discuss how JAK inhibitors have come under scrutiny in the past for systemic adverse effects in oral formulations, while exploring the safety data of topical JAK inhibitors in the pediatric population, which appears to show a more favorable risk profile with localized effects.

Aaron Farberg, MD, discusses how, when prescribing therapies for pediatric patients, dermatologists prioritize long-term safety alongside efficacy. Topical Janus kinase (JAK) inhibitors have demonstrated a favorable safety profile compared with their oral counterparts, with minimal systemic absorption. Appropriate monitoring may include baseline blood work and periodic clinical assessments, particularly in younger children. Effective parent education balances transparent discussion of potential adverse effects with evidence-based reassurance about the therapy’s safety profile.

Jiyeon Oh’s research confirms that a personalized approach is needed to treat all complexities associated with AD.

Researcher Jiyeon Oh shares results of a recent study that confirm the prevalence of AD is stable, but disease burden is rising.